In a report released today, Eric Joseph from J.P. Morgan maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price target of $67.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Eric Joseph’s rating is based on a combination of factors that highlight the potential for PTC Therapeutics to achieve significant growth. The company’s recent earnings report showed a stronger-than-expected revenue performance, with first-quarter revenue surpassing consensus estimates. This was largely driven by the company’s collaboration revenue and strong sales from its existing products, Translarna and Emflaza. Despite some regulatory challenges in the European market, PTC Therapeutics remains optimistic about its revenue generation capabilities.
Additionally, Eric Joseph sees potential upside in the company’s late-stage clinical pipeline and upcoming regulatory milestones. The anticipated regulatory decisions for Sephience and Vatiquinone, as well as the strategic partnerships and commercial prospects for these products, contribute to the positive outlook. The current market conditions, including a recent pullback in share prices, present an attractive entry point for investors, making the stock a compelling buy opportunity according to Joseph’s analysis.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.